Pleco is developing novel treatments designed to detoxify the cancer-promoting cellular microenvironment. The treatments will be deployed as adjunctive therapy to existing therapies. We use a novel approach that aims to increase the sensitivity of cancer cells to therapy rather than just fighting them harder.

The Pleco approach justifies the classification ‘First-in-Class’ product that addresses one of the underlying causes of cancer, not the tumour itself. We have named such products Plecoid™ agents after the Plecostomus fish that clean an aquarium from the inside.

The first-generation Plecoid™ agents will consist of Active Pharmaceutical Ingredients (APIs) that are known and considered well-tolerated in humans. Second generation Plecoid™ products may include new chemical entities.